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Abstract
Background: Most HIV infections are transmitted across mucosal epithelium. Understanding the role of innate and specific
mucosal immunity in susceptibility or protection against HIV infection, as well as the effect of HIV infection on mucosal
immunity, are of fundamental importance. HLA-G is a powerful modulator of the immune response. The aim of this study
was to investigate whether soluble HLA-G (sHLA-G) expression in the female genital tract is associated with HIV-1 infection.
Methods and Findings: Genital levels of sHLA-G were determined in 52 HIV-1-uninfected and 44 antiretroviral naı ¨ve HIV-1-
infected female commercial sex workers (CSWs), as well as 71 HIV-1-uninfected non-CSW women at low risk of exposure,
recruited in Cotonou, Benin. HIV-1-infected CSWs had higher genital levels of sHLA-G compared with those in both the HIV-
1-uninfected CSW (P=0.009) and non-CSW groups (P=0.0006). The presence of bacterial vaginosis (P=0.008), and HLA-
G*01:01:02 genotype (P=0.002) were associated with higher genital levels of sHLA-G in the HIV-1-infected CSWs, whereas
the HLA-G*01:04:04 genotype was also associated with higher genital level of sHLA-G in the overall population (P=0.038).
When adjustment was made for all significant variables, the increased expression of sHLA-G in the genital mucosa remained
significantly associated with both HIV-1 infection (P=0.02) and bacterial vaginosis (P=0.03).
Conclusion: This study demonstrates that high level of sHLA-G in the genital mucosa is independently associated with both
HIV-1 infection and bacterial vaginosis.
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Introduction
HIV vaccines and microbicides hold promise for preventing the
acquisition of HIV-1 infection [1,2] but successful design of such
agents requires a clear understanding of the mechanisms of HIV-1
transmission at the initial site of infection [3]. Most HIV-1
infections occur during heterosexual intercourse, and women are
more likely to become infected than men [4]. Initial exposure to
HIV-1 during sexual transmission occurs in the genital tract;
however, little is known about HIV-1-specific immune responses
at this site, as well as the effect of HIV-1 on mucosal immunity.
Human leukocyte antigen (HLA)-G is a non-classical major
histocompatibility class I protein, characterised by limited
polymorphism and tissue-restricted distribution. HLA-G is ex-
pressed as membrane-bound (HLA-G1, -G2, -G3 and -G4) and
soluble (HLA-G5, -G6, -G7) isoforms as a result of alternative
splicing [5]. The major isoforms present in the plasma are soluble
HLA-G (sHLA-G)-1 and -G5 which are generated by shedding or
proteolytic cleavage of membrane-bound HLA-G1 isoform and by
secretion of a soluble form, respectively. Under physiological
conditions, sHLA-G levels correlate with gender and HLA-G
genetic polymorphisms. The level of sHLA-G is higher in women
than in men [6]. Healthy individuals carrying the HLA-
G*01:01:03 and HLA-G*0105N alleles have lower plasma
sHLA-G levels than subjects carrying the more frequent HLA-
G*01:01:01 allele. In addition, individuals with the latter allele
have lower plasma sHLA-G levels than those with the HLA-
G*01:04 allele. Polymorphisms in the 39-untranslated region
(39UTR) can also affect the production of HLA-G molecules. The
presence of a 14-bp sequence insertion in HLA-G 39UTR has
been associated with lower levels of sHLA-G in serum of healthy
subjects [7–9]. HLA-G expression can be induced during
pregnancy [10], antiretroviral (ART) therapy [11,12] and in
pathological conditions such as autoimmune diseases, cancers,
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inhibit the activity and mediate apoptosis of natural killer (NK)
cells and cytotoxic CD8
+ T cells [14–17], as well as CD4
+ T cell
proliferation [18] and induce tolerogenic dendritic cells (DC) and
regulatory T cells [19–22].
The immunosuppressive properties of HLA-G might contribute
to the susceptibility to HIV-1 infection. Recent studies have shown
that HLA-G polymorphisms are associated with altered risks of
heterosexual acquisition [23–25] and vertical transmission [26,27]
of HIV-1. Plasma sHLA-G expression, at the protein level, was
recently associated with increased risk of HIV-1 infection and
more rapid disease progression [19,28,29]. However, initial
exposure to HIV-1 during sexual transmission occurs in the
female genital tract and no data are available on the possible
association between genital HLA-G expression and susceptibility
to HIV-1 infection. We have therefore measured the genital levels
of sHLA-G in HIV-1-infected and HIV-1-uninfected female
commercial sex workers (CSWs), as well as HIV-1-uninfected
non-CSW women at low risk for exposure to investigate whether
sHLA-G expression is associated with HIV-1 infection.
Methods
Study population
Female CSWs were enrolled through a dedicated sex worker
clinic in Cotonou, Benin and were divided into two groups: HIV-
1-uninfected CSWs (n=52) and ART-naı ¨ve HIV-1-infected
CSWs (n=44). The HIV-1-uninfected non-CSW control subjects
at low risk for exposure (n=71) were enrolled from a general
health clinic in Cotonou. Women were invited to participate in the
study as they attended clinics. Women were excluded from the
study if ,18 years old, menstruating, or pregnant. At enrolment,
participants were asked to answer a questionnaire about
demographic information, sexual behaviour, duration of prostitu-
tion, number of sex partners, condom use, vaginal douching
practices, and reproductive history. Each participant underwent a
genital examination by a physician. Vaginal specimens were
obtained for diagnosis of candidiasis and bacterial vaginosis by
microscopic examination. Endocervical swabs were obtained to
test for Neisseria gonorrhoeae and Chlamydia trachomatis infection using
BD ProbeTec ET system (Strand Displacement Assay, Becton
Dickinson, Heidelberg, Germany). Peripheral blood was taken for
HIV, HLA-G and CCR5 genotype analyses. Plasma and serum
were kept frozen at - 80uC until use. HIV-1 positivity was defined
by the presence of HIV-1 antibodies tested with Vironostika HIV
Uni-Form II Ag/Ab (Organon Teknika, Boxtel, The Netherlands).
Non-reactive samples were considered HIV-seronegative, whereas
reactive samples were tested with Genie II HIV-1/HIV-2 (Bio-
Rad, Hercules, CA). Genie II dually reactive samples (to HIV-1
and HIV-2) and discordant samples (Vironostika reactive/Genie II
non-reactive) were further tested by INNO-LIA HIV I/II Score
(Innogenetics NV, Technologiepark 6, Gent, Belgium). Viral loads
were determined in the plasma of all HIV-1 infected CSWs using
VERSANT HIV-1 RNA 3.0 Assay (bDNA) (Siemens Medical
Solutions Diagnostics, Tarrytown NY). DNA samples were
genotyped for the CCR5 32-bp deletion allele and all women
were found to be homozygous for the wild-type allele.
Mucosal sample collection and preparation
Cervicovaginal lavage (CVL) samples were obtained from all
study participants by a physician, using a 10-ml syringe filled with
sterile phosphate-buffered solution and aimed directly into the
cervical os. CVL fluids were then collected, transferred immedi-
ately into 20 ml of RPMI-1640, kept on ice, and processed within
1 hour. CVL samples were centrifuged at 1500 r.p.m. for 10 min
to remove cells and debris, and supernatants were stored at
280uC until shipped on dry ice to Montre ´al, Canada. CVL
samples were concentrated with Amicon Ultra-15 5 kDa (Milli-
pore, Billerica MA) prior to sHLA-G measurement.
Soluble HLA-G measurements and HLA-G genotyping
sHLA-G CVL levels were measured using the Human sHLA-G
Immunoassay kit (Alexis Biochemicals, San Diego, CA, USA),
which allows simultaneous detection of HLA-G1 and -G5 soluble
proteins without discrimination. The final concentration of sHLA-
G in the CVL sample was determined as follows: concentration
obtained with the sHLA-G Elisa assay (units per ml)/(CVL
concentration factor)6total CVL volume prior to concentration.
HLA-G alleles were determined by direct DNA sequencing
analysis of the nucleotide regions encompassing HLA-G exons
2–4 and using purified DNA from blood samples as described
previously [30]. HLA-G 3-UTR polymorphisms were determined
according to the protocol previously described by [31].
Statistical analysis
Statistical analysis was performed using the GraphPad PRISM
5.0 for Windows (GraphPad Software, San Diego, CA). One-way
analysis of variance and Chi-square tests were used to assess the
significance of the associations between continuous and categorical
variables across all study groups. Comparisons of continuous and
categorical variables between two groups were assessed by the
Mann-Whitney U and Chi-square or Fisher exact tests, respec-
tively. Spearman’s rank test was used to determine correlations
between continuous variables. Multiple logistic regression analysis
was used to define independent predictors identified as significant
in the crude analysis. Odds ratio (OR) and 95% confidence
interval (CI) were calculated with the exact method. Differences
were considered significant at P#0.05 or P#0.015 when
comparing two or three groups, respectively.
Ethics statement
Written informed consent was obtained from all subjects who
participated in the study and the investigation reported in this
paper was approved by the Comite ´ National Provisoire d’E ´thique
de la Recherche en Sante ´ in Cotonou and the CHUM Research
Ethics Committee.
Results
Sociodemographic and clinical characteristics of the study
population are described in Table 1. These data were collected to
address the issue of confounding variables for risk of HIV-1
infection. The three groups were similar with respect to age, days
from last menses, vaginal douching, and the presence of vaginal
candidiasis. The HIV-1-infected CSWs were more likely to have a
bacterial vaginosis (P=0.003) than the HIV-1-uninfected non-
CSWs. The HIV-1-unifected non-CSWs, were less likely to have
Chlamydia trachomatis or Neisseria gonorrhoeae genital infections than
the HIV-1-uninfected (P=0.027) and HIV-1-infected (P=0.022)
CSW groups. The average number of clients was higher in HIV-1-
uninfected CSWs than in HIV-1-infected CSWs (P=0.044),
whereas the duration of sex work, and condom use were
equivalent between the two CSW groups.
HIV-1-infected CSWs had significantly higher levels of sHLA-G
in their CVL samples (946145 units/ml) than did the HIV-1-
uninfected CSWs (35653 units/ml; P=0.009) and the HIV-1-
uninfected non-CSW women (26653 units/ml; P=0.0006)
(Figure 1). There was no significant correlation between the
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HIV-1-infected CSWs (r
2=20.162, P=0.344).
Since sHLA-G expression has been associated with HLA-G
polymorphism [7–9], we looked at the distribution of sHLA-G
levels, either between study groups or in the total population,
according to the HLA-G genetic variants (Table 2). The HLA-
G*01:01:02 genotype, in the heterozygous or homozygous states,
was associated with increased expression of genital sHLA-G in
HIV-1-infected CSWs compared with those in both the HIV-1-
uninfected CSW (P=0.051) and non-CSW (P=0.002) groups. In
the overall population, women carrying the HLA-G*01:04:04
heterozygous or homozygous genotypes expressed the highest
levels of genital sHLA-G molecules when compared with those
expressed by women harbouring other genotypes (P=0.038).
However, there was no significant association between HLA-G
alleles and sHLA-G levels within the three groups taken
separately. Because HLA-G polymorphism can also be associated
with HIV-1 infection [23–27], we looked at the distribution of the
HLA-G genetic variants among the study groups (Table 2) and
found no significant association between HLA-G alleles and HIV-
1 infection (data not shown). The presence of bacterial vaginosis
could potentially affect the genital level of sHLA-G molecules and
since the rate of bacterial vaginosis was significantly higher in the
HIV-1-infected CSWs (Table 1), we investigated the possible
correlation between sHLA-G levels and the presence of bacterial
vaginosis (Table S1). We found that the expression of sHLA-G in
genital samples was significantly associated with bacterial vaginosis
among the HIV-1-infected CSWs (P=0.035).
When adjustment was made for all significant variables found in
the crude analysis (HIV-1 infection, bacterial vaginosis, HLA-
G*01:01:02 and HLA-G*01:04:04 genotypes), the expression of
sHLA-G in the genital mucosa remained significantly associated
with both HIV-1 infection (OR: 3.0, 95% CI=1.17–7.53,
P=0.02) and bacterial vaginosis (OR 3.4, 95% CI=1.10–10.5,
P=0.03).
Discussion
High level of sHLA-G in the genital mucosa is associated with
HIV-1 infection in Beninese CSWs. In the present study, we have
carefully controlled for potential confounding factors that could
influence HLA-G expression such as gender [6], pregnancy [10],
ART therapy [11,12] and HLA-G polymorphism [7–9]. All study
participants were ART-naı ¨ve nonpregnant women. The HLA-
G*01:01:02 and HLA-G*01:04:04 genotypes were significantly
associated with sHLA-G expression in the crude analysis but these
Table 1. Distribution of demographic, sexual behaviour and genital tract infection characteristics in HIV-1-uninfected CSWs, HIV-1-
infected CSWs, and HIV-1-uninfected non-CSW women.
HIV-1-uninfected HIV-1-infected HIV-1-uninfected p
CSWs CSWs non-CSWs value
a
N=52 N=44 N=71
Age, mean (SD), years 34.4 (12.3) 34 (8.7) 32.6 (9.4) NS
Duration of sex work, mean (SD), years 4.3 (3.2) 4.1 (2.6) NA NS
Number of clients last week, mean (SD) 17.1 (14.0) 11.3 (11.0) NA 0.044
Days since last menses, mean (SD) 17.1 (13.0) 18.2 (15.4) 19.1 (12.3) NS
Vaginal douching 50/52 (96%) 42/43 (98%) 65/71 (93%) NS
Condom always used with clients past month 39/52 (75%) 22/39 (56%) NA NS
Bacterial vaginosis 33/51 (65%) 34/43 (79%) 36/71 (51%) 0.009
b
Candidiasis 4/51 (8%) 5/44 (11%) 15/71 (21%) NS
NG and/or CT infections 7/46 (15%) 6/39 (15%) 2/72 (3%) 0.029
c
CSW, commercial sex worker; HIV-1, human immunodeficiency virus type 1; N: number of participants; NA: non applicable; NG/CT: Neisseria gonorrhoeae/Chlamydia
trachomatis, NS: nonsignificant; SD, standard deviation.
aP-values for the comparison across all groups were calculated with one-way ANOVA analysis of variance for the age and days since last menses; Mann-Whitney U test
for the duration of sex work and average number of clients; Chi-square test for vaginal douching, condom use, bacterial vaginosis, candidiasis, and NG/CT infections.
bP=0.125 for the comparison between HIV-1-uninfected CSWs and HIV-1-infected CSWs, P=0.105 for the comparison between HIV-1-uninfected CSWs and HIV-1-
uninfected non-CSWs, and P=0.003 for the comparison between HIV-1-infected CSWs and HIV-1-uninfected non-CSWs as determined by Chi-square test.
cP=0.987 for the comparison between HIV-1-uninfected CSWs and HIV-1-infected CSWs, P=0.027 for the comparison between HIV-1-uninfected CSWs and HIV-1-
uninfected non-CSWs, and P=0.022 for the comparison between HIV-1-infected CSWs and HIV-1-uninfected non-CSWs as determined by Fisher exact test.
doi:10.1371/journal.pone.0025185.t001
Figure 1. Mean genital soluble HLA-G levels according to the
study groups. Statistical significance of differences in the genital
levels were evaluated with the Mann-Whitney U test. CSW, commercial
sex worker; HIV-1, human immunodeficiency virus type 1.
doi:10.1371/journal.pone.0025185.g001
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infection. In contrast to previous studies [23–25], HLA-G
polymorphism was not associated with risk of HIV-1 infection
among the Beninese CSWs. The relatively small number of
subjects analysed in each groups have limited the power of the
present study to reproduce previous findings.
We have previously measured the level of sHLA-G in the blood
of these women and found that HIV-infected CSWs had lower
plasma levels when compared to HIV-uninfected CSWs and non-
CSWs. This is in sharp contrast with that found in the genital
mucosa of these women. The discordance in the production of
sHLA-G between the two compartments may depend on local
factors such as immune cells, micro-organisms and derived
products that could affect sHLA-G expression. sHLA-G plays a
crucial role in the regulation of both innate and adaptive immunity
by modulating the function of DC, NK and T lymphocytes [14–
22]. These effects depend on interactions of HLA-G molecules
with inhibitory receptors expressed on myeloid cells (immunoglo-
buline-like transcripts (ILT)-4), on myeloid and lymphoid cells
(ILT-2) and on NK cells (killing inhibitory receptor (KIR)-2DL4)
[32]. The outcome of the immune response may therefore vary
according to the specific interactions of sHLA-G with the different
types of cells and receptors. Interaction of sHLA-G with ILT-2
receptor on DC and NK cells decreased the release of interferon
(INF)-gamma and increased the production of interleukin (IL)-10
and transforming growth factor (TGF)-beta [33,34]. IL-10 has
been shown to induce HLA-G expression [35] and HLA-G can
also stimulate IL-10 expression in peripheral blood monocytes
[36]. Triggering ILT-4 by sHLA-G induces tolerogenic DC and T
regulatory cells [20,37]. On the other hand, interaction of sHLA-
G with KIR2DL4 receptor on peripheral blood monocytes and
NK cells promotes the production of pro-inflammatory cytokines
and chemokines [36,38–40]. We have previously measured the
cytokine and chemokine expression patterns in the genital samples
of our study subjects and found that HIV-1-infected CSWs had
significantly higher levels of IFN-gamma tumor necrosis factor
(TNF)-alpha, monocyte chemotactic protein (MCP-3/CCL7) and
monokine induced by IFN-gamma (MIG/CXCL9) compared
with those in both the HIV-1-uninfected CSW and non-CSW
groups [41,42]. The same observations were made for IL-1 beta
and IL-8 (data unpublished). High level of IL-1 beta and TNF-
alpha in the female genital tract has been associated with
enhanced HIV-1 shedding at this site [43]. The inflammatory
response observed in the genital mucosa of HIV-1-infected women
may promote the recruitment, differentiation and activation of
immune cells, which act as targets favouring viral replication and
viral dissemination at the initial site of infection. As to whether
sHLA-G is directly involved in the induction of such mucosal
inflammation via its interaction with KIRD2L4 on monocytes and
NK cells in the female genital tract remains to be confirmed.
Although the genital mucosa levels of sHLA-G correlate
significantly with those of the cytokines and chemokines in the
HIV-1-uninfected groups, these correlations were not significant in
the HIV-1-infected CSW group (Tables S2 and S3). Thus, in the
absence of HIV-1, genital levels of the immunosuppressive sHLA-
G molecules and pro-inflammatory cytokines and chemokines are
low and correlate to maintain mucosal homeostasis. Conversely, in
the presence of HIV-1, there is an aberrant and independent
production of both factors in the female genital tract that may
reflect a viral strategy of immune piracy, allowing for the
simultaneous production of chemokines/cytokines to recruit and
activate HIV-1 target cells and sHLA-G to induce immune
tolerance towards HIV-1.
Interestingly, the increased level of sHLA-G in genital samples
was also significantly associated with the presence of bacterial
vaginosis. Although HIV-1-infected CSWs had higher levels of
sHLA-G and were more likely to have a bacterial vaginosis than
the HIV-1-uninfected non-CSWs, the association between sHLA-
Table 2. Genital soluble HLA-G levels in HIV-1-uninfected CSWs, HIV-1-infected CSWs, and HIV-1- uninfected non-CSW women
according to the HLA-G gene polymorphism.
HLA-G HIV-1- uninfected HIV-1-infected HIV-1 uninfected P-value
a Total population P-value
b
CSWs CSWs non-CSWs
allele
c N Levels N Levels N Levels N Levels
01:01:01 34 59.4 (148) 20 113 (230) 33 48.0 (86) NS 87 67.0 (152) NS
01:01:02 15 64.5 (203) 14 191 (259) 15 3.9 (12) 0.034
d 44 84.0 (200) NS
01:03 11 47.8 (73) 11 59.4 (109) 8 12.2 (27) NS 30 42.6 (81) NS
01:04:01 4 48.2 (96) 7 171 (228) 14 18.0 (49) NS 25 65.6 (142) NS
01:04:04 20 118 (248) 19 118 (165) 12 31.8 (59) NS 51 97.6 (188) 0.038
0105N 8 30.7 (32) 5 67.4 (151) 10 14.1 (42) NS 23 31.5 (75) NS
39UTR SNP
e
3777 (c/c) 12 81.8 (228) 5 61.6 (107) 13 6.5 (21) NS 30 45.8 (151) NS
3952 (a/a) 27 86.7 (217) 11 64.6 (134) 27 39.1 (77) NS 65 64.0 (158) NS
14-bp (I/I) 6 16.4 (36) 7 97.7 (135) 6 0.45 (1.1) NS 19 41.3 (92) NS
CSW, commercial sex worker; HIV-1, human immunodeficiency virus type 1; I, insertion,
N, number of participants; NS, nonsignificant; SD, standard deviation; SNP, single nucleotide polymorphism; UTR, untranslated region.
Data are mean (SD).
aP-values for the comparison between all groups were calculated with one-way analysis of variance test.
bP-values were calculated with Mann-Whitney U test.
cPresence of the allele in the homozygous or heterozygous states.
dP=0.051 for the comparison between HIV-1-uninfected CSWs and HIV-1-infected CSWs, P=0.153 for the comparison between HIV-1-uninfected CSWs and HIV-1-
uninfected non-CSWs and P=0.002 for the comparison between HIV-1-infected CSWs and HIV-1-uninfected non-CSWs as determined by Mann-Whitney U test.
ePresence of the variants in the homozygous state.
doi:10.1371/journal.pone.0025185.t002
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adjusting for HIV-infection. This suggests that genital sHLA-G
level is independently associated with both bacterial vaginosis and
HIV-1 infection. Bacterial vaginosis is an established risk factor for
HIV infection [44,45]. It has been suggested that bacterial
vaginosis increases risk of HIV infection by inducing a clinical
or subclinical mucosal inflammatory response, recruiting target
cells and breaching of intact cervico-vaginal mucosa [46]. Indeed,
bacterial vaginosis has been associated with increased levels of IL-1
beta, IL-6, IL-8, IL-10 and TNF-alpha, RANTES (CCL5),
macrophage inflammatory protein (MIP-1 alpha/CCL3) and
MIP-1 beta (CCL4) in genital samples [47–49]. However,
bacterial vaginosis was not associated with the production of
these cytokines and chemokines in the genital tract of the Beninese
women (Tables S4 and S5).
Altogether, these results suggest that in the context of HIV-1
infection, sHLA-G expression in the female genital tract is a
complex process modulated by many factors such as HIV-1,
bacterial vaginosis HLA-G genotypes, and cytokine/chemokine
expression patterns, which may all contribute to an immunological
environment promoting viral replication and escape from the
mucosal immune response.
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